Jazz Pharmaceuticals files Form 144 to sell common stock

Jazz Pharmaceuticals submitted a Form 144 indicating intended sales of common stock through Merrill Lynch with an associated date of 03/03/2026.

Rhea-AI Filing Summary

Jazz Pharmaceuticals submitted a Form 144 indicating intended sales of common stock through Merrill Lynch with an associated date of 03/03/2026. The filing lists stock option-related lots dated 11/01/2021 (483 shares), 12/01/2021 (2,952 shares) and 01/03/2022 (2,565 shares).

Insights

Securities Compliance Attorney

Form 144 reports an intended sale of restricted/common shares via a broker.

The filing names Merrill Lynch as the broker and notes an associated date of 03/03/2026. The listed lots are tied to stock options with grant/exercise dates and explicit share counts: 11/01/2021 (483), 12/01/2021 (2,952) and 01/03/2022 (2,565).

Timing, exact proceeds treatment, and whether sales occurred in the past three months are not detailed in the excerpt; subsequent transaction reporting or brokerage confirmations would clarify execution and Rule 144 compliance.

Equity Markets Analyst

Listed option lots quantify potential near-term share supply from an insider-related sale.

The excerpt shows three option-derived share amounts totaling 5, (follow the counts above) as discrete lots; each lot is labeled with its grant/exercise date and share count which market participants may watch as possible supply.

Actual market impact depends on whether and when those shares are sold; the excerpt does not state execution, pricing, or proceeds recipients.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Jazz Pharmaceuticals' Form 144 (JAZZ) show?

The filing lists intended sales of common stock through Merrill Lynch, with an associated date of 03/03/2026 and specific option-derived lots dated 11/01/2021, 12/01/2021, and 01/03/2022.

How many shares are listed on the Form 144 for JAZZ?

The excerpt lists three option-related lots: 483, 2,952, and 2,565 shares tied to dates 11/01/2021, 12/01/2021, and 01/03/2022, respectively.

Does the Form 144 confirm the shares were sold for Jazz Pharmaceuticals (JAZZ)?

No. The Form 144 excerpt indicates an intended or reported sale method but does not confirm execution, proceeds, or sale prices; execution details are not provided in the excerpt.

Who is listed as the broker on the JAZZ Form 144?

The broker named in the excerpt is Merrill Lynch with an address noted at 3075A Hansen Way, 1st Floor, Palo Alto, CA, as the listed intermediary for the transactions.

Are there disclosures about sales in the past three months in this excerpt?

The excerpt includes a heading for 'Securities Sold During The Past 3 Months' but provides no details under that heading in the provided content.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 02:35 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001193210
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Jazz Pharmaceuticals Plc
SEC File Number	001-33500
Address of Issuer	5th Floor Waterloo Exchange Waterloo Road Dublin IRELAND D04 E5W7
Phone	353-1-634-7800
Name of Person for Whose Account the Securities are To Be Sold	Bruce C Cozadd
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill Lynch 3075A Hansen Way 1st Floor Palo Alto CA 94304	6000	1118613.32	61560350	03/03/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/01/2021	Stock Option	Jazz Pharmaceuticals PLC			483	11/01/2021	Cash
Common	12/01/2021	Stock Option	Jazz Pharmaceuticals PLC			2952	12/01/2021	Cash
Common	01/03/2022	Stock Option	Jazz Pharmaceuticals PLC			2565	01/03/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	03/03/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/26/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Bruce C Cozadd
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)